← Leaderboards
Sridhar Varadarajan
P2d, Inc.
$475,783
Attributed
$951,565
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $447K · FY2018–23$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$951,565 · 2
By mechanism
R44$504,565 · 1
R15$447,000 · 1
Top collaborators
- Somasundar Prasad Gabbita2 shared
- Arthur R Frampton1 shared
Others in their field
Other Emerging Leaders on “Analog”
- John Hobbs · Suny At Stony Brook$41,239,084
- Christopher Bee · Suny At Stony Brook$41,239,084
- John Damon Chodera · Sloan-Kettering Inst Can Research$15,023,002
- Jeffrey Reich · Sparian Biosciences, Inc.$14,845,721
- Thomas Dick · Rbhs-New Jersey Medical School$14,469,725
- Terry Roemer · Prokaryotics, Inc.$14,198,753
Research focus
AnalogGenesFutureCytokineCognitive FunctionComplement C2aChronicBudgetsAffectChemical SynthesisClinical ResearchCognitive DeficitsCognitive PerformanceAnimal Disease ModelsBrainAge RelatedApplications GrantsAlzheimer&AposAmyloid Beta-ProteinBinding ProteinsAmyloid Precursor Protein ProcessingCardiovascular SystemBrain NeoplasmsCanis Familiaris
Grant awards (3)
Enhanced delivery of site-specific DNA damaging toxins to prostate cancercells$447,000
R15 · FY2023 · CA · contact PI
A first-in-class orally active anti-TNF-alpha inhibitor to treat AD$166,732
R44 · FY2019 · AG
A first-in-class orally active anti-TNF-alpha inhibitor to treat AD$337,833
R44 · FY2018 · AG